A risk-benefit assessment of metformin in type 2 diabetes mellitus.
about
Metformin in reproductive health, pregnancy and gynaecological cancer: established and emerging indicationsRepurposing metformin: an old drug with new tricks in its binding pocketsMetformin added to insulin therapy for type 1 diabetes mellitus in adolescentsUse of metformin in diseases of agingMetformin: Current knowledgeThe relationship between metformin therapy and the fasting plasma lactate in type 2 diabetes: The Fremantle Diabetes StudyMetformin's contraindications should be contraindicated.Anti-Hyperglycemic Properties of Crude Extract and Triterpenes from Poria cocos.Pharmacological treatment of obesity in patients with polycystic ovary syndrome.Influence of ω-3 fatty acid eicosapentaenoic acid on IGF-1 and COX-2 gene expression in granulosa cells of PCOS women.Metformin extended release for the treatment of type 2 diabetes mellitus.Safety, tolerability, and efficacy of metformin extended-release oral antidiabetic therapy in patients with type 2 diabetes: an observational trial in AsiaThe Effect of Nizatidine, a MATE2K Selective Inhibitor, on the Pharmacokinetics and Pharmacodynamics of Metformin in Healthy VolunteersAntidiabetic effect and mode of action of cytopiloyneHerbal therapies for type 2 diabetes mellitus: chemistry, biology, and potential application of selected plants and compoundsMetformin treatment in diabetes and heart failure: when academic equipoise meets clinical reality.Metformin therapy and clinical uses.Genetic polymorphisms potentially associated with response to metformin in postmenopausal diabetics suffering and not suffering with cancer.Saxagliptin plus metformin combination in patients with type 2 diabetes and renal impairment.Combination of glibenclamide-metformin HCl for the treatment of type 2 diabetes mellitus.Pharmacokinetic considerations for the treatment of diabetes in patients with chronic kidney disease.Metformin; a review of its history and future: from lilac to longevity.Expression and regulation of INTELECTIN1 in human granulosa-lutein cells: role in IGF-1-induced steroidogenesis through NAMPT.Patients With Type 2 Diabetes: Anesthetic Management in the Ambulatory Setting: Part 2: Pharmacology and Guidelines for Perioperative Management.Metformin prevents an adaptive increase in GSH and induces apoptosis under the conditions of GSH deficiency in H4IIE cells.Impact of Japanese regulatory action on metformin-associated lactic acidosis in type II diabetes patients.Toward the prediction of FBPase inhibitory activity using chemoinformatic methods.Pharmacokinetic-Pharmacodynamic Modeling of Metformin for the Treatment of Type II Diabetes Mellitus.Insulin sensitivity during oral glucose tolerance test and its relations to parameters of glucose metabolism and endothelial function in type 2 diabetic subjects under metformin and thiazolidinedione.Contraindications to metformin therapy in patients with Type 2 diabetes--a population-based study of adherence to prescribing guidelines.Long-term glycaemic improvement after addition of metformin to insulin in insulin-treated obese type 2 diabetes patients.Improved glycaemic control with metformin-glibenclamide combined tablet therapy (Glucovance) in Type 2 diabetic patients inadequately controlled on metformin.Importance of creatinine clearance for drug dosing in nursing home residents.[Proximal femoral fractures in the German external quality assurance module 17/1: reasons for delay in surgery].Clinical development of metformin extended-release tablets for type 2 diabetes: an overview.Establishing pragmatic estimated glomerular filtration rate thresholds to guide metformin prescribing: careful assessment of risks and benefits is required.Effects of an Herbal Combination on Glycemic Control and Lipid Profile in Diabetic Women: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial.Effects of metformin on bovine granulosa cells steroidogenesis: possible involvement of adenosine 5' monophosphate-activated protein kinase (AMPK).Initial treatment with rosiglitazone/metformin fixed-dose combination therapy compared with monotherapy with either rosiglitazone or metformin in patients with uncontrolled type 2 diabetes.Association of metformin administration with gut microbiome dysbiosis in healthy volunteers
P2860
Q22242884-988C1F3B-A183-4AB9-8510-487A95AAF056Q22250976-F99BBF35-F32C-460A-8792-B14E26E76FF6Q24241119-EEC72972-84DF-4035-92AE-24558CBF1ABBQ26828760-CA314449-A082-4F56-82E7-2C55D48CA105Q26853666-3DF692FC-9137-4B63-9A7B-D734E29E0180Q28345534-57B70313-DDEE-43D7-8869-B0C77969FF2CQ33920606-0D715201-0DD2-4C38-BB13-EFE286547584Q34173158-C944312B-6562-4BAF-B628-17816E516AFEQ34442683-28BA7D23-F74B-4F4F-A649-681D8E1C0316Q35589228-57CF8B54-D1BB-41FA-889C-933170E5B514Q36429747-166CEBBF-8FC1-4AAB-AA65-6E5D261EDA46Q36546955-D1A28641-E0DE-491B-A0C4-5AF295D183F8Q36689589-2D4B23F1-F6A4-4FCC-A328-B7FC8AB8DA24Q36723068-5D4BF6CA-CD94-49E4-95E7-155961982D7EQ36801780-09DEB11B-8664-4E6E-9422-802A59E46D64Q37102216-394D7642-928D-49E9-82FC-6CB763FDB3BAQ37262966-6C8C95A7-57A0-4531-BC21-A01ECB68E334Q37521408-47FB6B86-3AE0-4690-BBAC-14A4DA5236A5Q37982112-BE1D97AF-8B80-4C88-9DB2-D7FF94ED72C9Q38057019-76803A9D-D187-4987-A955-53F887A659D8Q38086611-8229CF09-441D-4A02-9C32-D6659EE55A49Q38774878-C8717255-BF58-41FD-9F2B-618B99DEC9ACQ38983232-04742E3A-E9D2-4682-BD07-AA4717A38581Q39106418-6C992F35-ACD4-4E00-A2DF-4BCA10C03990Q40102345-9BC3328F-28B6-4742-A81B-557CEA5F8B1EQ41141739-42D62874-0B03-48F6-A637-89A719C60686Q42237895-E68149F8-838C-4965-B19E-75DF3BB634D6Q42259240-54BA8F94-7C35-4AD5-92F0-1F1404E5B7B3Q42499990-6FA783DE-7FBF-4279-BE82-EF4627A63277Q43687476-92978693-B6CB-4DBB-B245-84806F95C079Q43923311-832694A1-2CE9-4E51-B10C-8A67CA1101B5Q44082233-07983458-54B5-48F7-B013-33709E06F9F1Q45122634-1EA6AB7A-2A40-4C32-AFE2-E54AC4FC9D9CQ46221153-A4360CAC-2977-4644-8013-6BB11F01FBD9Q46415820-61B77F35-4533-417F-9863-A6363B655B50Q46697318-46709487-57F1-4CDE-BFBB-9084D6999C6AQ49926482-8BB3A427-E730-4D44-AF4B-0CA2C8879C9BQ50642410-7DC043A7-69ED-444C-B821-D1027CD9C095Q51488169-09AA2110-7B84-4CD6-9F63-C1154C05E2FFQ58691643-556C00DF-BB78-4982-8194-A7B0AEAFB3FC
P2860
A risk-benefit assessment of metformin in type 2 diabetes mellitus.
description
1999 nî lūn-bûn
@nan
1999 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի հունիսին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
A risk-benefit assessment of metformin in type 2 diabetes mellitus.
@ast
A risk-benefit assessment of metformin in type 2 diabetes mellitus.
@en
type
label
A risk-benefit assessment of metformin in type 2 diabetes mellitus.
@ast
A risk-benefit assessment of metformin in type 2 diabetes mellitus.
@en
prefLabel
A risk-benefit assessment of metformin in type 2 diabetes mellitus.
@ast
A risk-benefit assessment of metformin in type 2 diabetes mellitus.
@en
P1433
P1476
A risk-benefit assessment of metformin in type 2 diabetes mellitus.
@en
P2093
C J Bailey
H C Howlett
P304
P356
10.2165/00002018-199920060-00003
P577
1999-06-01T00:00:00Z
P6179
1042971912